Indication
Blenrep is indicated in adults for the treatment of relapsed or refractory multiple myeloma: in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy; and in combination with pomalidomide and dexamethasone in patients who have received at least one prior therapy including lenalidomide.
In other countries
The same active substances on other registers, the same brand first.
National listings
The national registers that list this EU medicine.
- Blenrep 100 MG Polvo Para Concentrado Para Solucion Para PerfusionSpain · 110 mgMarketed
- Blenrep 70 MG Polvo Para Concentrado Para Solucion Para PerfusionSpain · 77 mgMarketed
- Blenrep 100 mg poeder voor concentraat voor oplossing voor infusieNetherlandsAuthorised
- Blenrep 70 mg poeder voor concentraat voor oplossing voor infusieNetherlandsAuthorised